SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA issues ‘DMF information request’ to SMS Pharmaceuticals

17 Sep 2019 Evaluate

US Food and Drug Administration (USFDA) has issued a ‘DMF information request’ to SMS Pharmaceuticals to provide the information to demonstrate its Ranitidine API manufacturing process does not contain NDMA impurity.

SMS Pharmaceuticals is a global player in API manufacturing having strong research and manufacturing team supported by state of art facilities.

SMS Pharmaceuticals Share Price

429.55 5.40 (1.27%)
17-Apr-2026 13:26 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.00
Dr. Reddys Lab 1229.30
Cipla 1237.80
Zydus Lifesciences 944.35
Lupin 2304.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×